This is a repository copy of *Mapping from the Health Assessment Questionnaire to the EQ-5D: The Impact of Different Algorithms on Cost-Effectiveness Results*.

Article:

Table 3: Results of published and rebuilt model

Treatment strategy	Published Model		Rebuilt Model	
	Cost	**QALYs**	**Cost**	**QALYs**
Adalimumab	£74,800 (£68,800, £81,000)	2.89 (-2.12, 7.87)	£73,100 (£69,900, £76,000)	2.84 (-1.79, 8.02)
Etanercept	£75,100 (£68,700, £81,500)	2.80 (-2.21, 7.84)	£74,700 (£71,400, £77,800)	2.77 (-1.89, 8.02)
Infliximab	£73,000 (£66,100, £79,700)	2.80 (-2.24, 7.84)	£69,800 (£63,500, £74,500)	2.75 (-1.87, 7.93)
Rituximab	£69,400 (£62,700, £76,400)	3.10 (-1.78, 7.95)	£69,400 (£63,600, £75,300)	3.12 (-1.51, 8.25)
Abatacept	£93,000 (£86,200, £100,100)	3.28 (-1.46, 8.05)	£94,500 (£90,500, £98,500)	3.29 (-1.25, 8.34)
DMARDs	£49,000 (£43,300, £54,900)	2.13 (-3.27, 7.46)	£45,100 (£42,700, £47,600)	2.11 (-2.55, 7.29)

DMARDs: disease modifying anti-rheumatic drugs, QALYs: quality-adjusted life years.